Cargando…
THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients
AIM: Several cases of small cell lung cancer (SCLC) patients demonstrate resistance to the treatment initiatives such as cisplatin after platinum chemotherapy. It is crucial to the improvement of the overall survival (OS) of SCLC patients to discover the gene mutation inducing platinum resistance wi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172928/ https://www.ncbi.nlm.nih.gov/pubmed/35685767 http://dx.doi.org/10.2147/DDDT.S363665 |
_version_ | 1784721934115667968 |
---|---|
author | Yao, Zifu Lin, Anqi Yi, Yonglin Shen, Weitao Zhang, Jian Luo, Peng |
author_facet | Yao, Zifu Lin, Anqi Yi, Yonglin Shen, Weitao Zhang, Jian Luo, Peng |
author_sort | Yao, Zifu |
collection | PubMed |
description | AIM: Several cases of small cell lung cancer (SCLC) patients demonstrate resistance to the treatment initiatives such as cisplatin after platinum chemotherapy. It is crucial to the improvement of the overall survival (OS) of SCLC patients to discover the gene mutation inducing platinum resistance within this cohort. PATIENTS AND METHODS: We analyzed the gene mutations significantly associated with the OS from 2 cohorts of SCLC platinum-treated patients. And then we screened out THSD7B mutation. In order to understand the mechanism between THSD7B mutation and platinum resistance, we designed gene mutation co-occurrence and mutual exclusivity analysis, gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) analysis, and Connectivity Map (CMap) analysis. RESULTS: The poor prognosis of THSD7B mutant patients may be related to the inhibition of cell death-related pathways, the up-regulation of cell invasion and metastasis pathways, and the down-regulation of immune response pathways. Lovastatin and cyclooxygenase inhibitors could be used as potential target compounds in THSD7B mutant patients, which provides reference for future research on platinum resistance. CONCLUSION: THSD7B can be considered a reliable biomarker that effectively facilitates the prediction of poor survival in SCLC platinum-treated patients. |
format | Online Article Text |
id | pubmed-9172928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-91729282022-06-08 THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients Yao, Zifu Lin, Anqi Yi, Yonglin Shen, Weitao Zhang, Jian Luo, Peng Drug Des Devel Ther Original Research AIM: Several cases of small cell lung cancer (SCLC) patients demonstrate resistance to the treatment initiatives such as cisplatin after platinum chemotherapy. It is crucial to the improvement of the overall survival (OS) of SCLC patients to discover the gene mutation inducing platinum resistance within this cohort. PATIENTS AND METHODS: We analyzed the gene mutations significantly associated with the OS from 2 cohorts of SCLC platinum-treated patients. And then we screened out THSD7B mutation. In order to understand the mechanism between THSD7B mutation and platinum resistance, we designed gene mutation co-occurrence and mutual exclusivity analysis, gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) analysis, and Connectivity Map (CMap) analysis. RESULTS: The poor prognosis of THSD7B mutant patients may be related to the inhibition of cell death-related pathways, the up-regulation of cell invasion and metastasis pathways, and the down-regulation of immune response pathways. Lovastatin and cyclooxygenase inhibitors could be used as potential target compounds in THSD7B mutant patients, which provides reference for future research on platinum resistance. CONCLUSION: THSD7B can be considered a reliable biomarker that effectively facilitates the prediction of poor survival in SCLC platinum-treated patients. Dove 2022-06-03 /pmc/articles/PMC9172928/ /pubmed/35685767 http://dx.doi.org/10.2147/DDDT.S363665 Text en © 2022 Yao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Yao, Zifu Lin, Anqi Yi, Yonglin Shen, Weitao Zhang, Jian Luo, Peng THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients |
title | THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients |
title_full | THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients |
title_fullStr | THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients |
title_full_unstemmed | THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients |
title_short | THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients |
title_sort | thsd7b mutation induces platinum resistance in small cell lung cancer patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172928/ https://www.ncbi.nlm.nih.gov/pubmed/35685767 http://dx.doi.org/10.2147/DDDT.S363665 |
work_keys_str_mv | AT yaozifu thsd7bmutationinducesplatinumresistanceinsmallcelllungcancerpatients AT linanqi thsd7bmutationinducesplatinumresistanceinsmallcelllungcancerpatients AT yiyonglin thsd7bmutationinducesplatinumresistanceinsmallcelllungcancerpatients AT shenweitao thsd7bmutationinducesplatinumresistanceinsmallcelllungcancerpatients AT zhangjian thsd7bmutationinducesplatinumresistanceinsmallcelllungcancerpatients AT luopeng thsd7bmutationinducesplatinumresistanceinsmallcelllungcancerpatients |